A Phase 1, First-in-Humans, safety study of SNSP113 in patients with Cystic Fibrosis.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs SYGN 113 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- 29 Jun 2017 Acoording to Synspira Media Release, this trail will initiate in early 2018.
- 10 Nov 2016 New trial record
- 27 Oct 2016 According to a Synedgen media release, the company expects to initiate this study in the year 2017.